Recently, a large observational real‐world study demonstrated that ET in combination with CDK4/6 inhibitor therapy significantly improved OS in an older population of patients with ER+/HER2– de novo advanced BC, who were enrolled in the US Medicare system. This evidence concerns the gene ESR1 and breast cancer.